' INTRODUCTION
Tetracyclines are a class of antibiotics with broad spectrum antibacterial activity. 1 Since the isolation of its first member, chlorotetracycline (1, Figure 1 ), from the culture broth of Streptomyces, 2 several generations of tetracycline analogs have been discovered and used to treat infections caused by a wide range of pathogens. These tetracyclines include oxytetracycline (2) , 3 tetracycline (3), 4 doxycycline (4), 5 and minocycline (5), 6 all discovered before the early 1970s, as well as the recently approved analog tigecycline (6) . 7 After a half century's use of tetracyclines, a high rate of resistance has emerged leading to dramatically decreased efficacy. 8 There are two main tetracycline-resistance mechanisms: (1) active drug efflux (tetAÀtetD, and tetKÀtetL) and (2) ribosomal protection (tetMÀtetO). 9 The efflux mechanism is mainly observed in Gram-negative organisms such as Escherichia coli and Pseudomonas spp., 9, 10 while ribosomal protection is more common in Gram-positive organisms such as Staphylococcus aureus and Streptococcus spp. 11 Since the discovery of the first generation of natural tetracyclines (chlorotetracycline, oxytetracycline, and tetracycline), several generations of non-natural tetracycline antibiotics have been produced to overcome tetracycline resistance. These include the clinically important doxycycline, minocycline, and tigecycline, which are derived from fermentation products through semisynthesis. However, due to the structural complexity and chemical sensitivity of the tetracycline scaffold, chemical modifications of tetracyclines in the past 50 years have been largely limited to substitution at C7 and C9, and very few modifications at C4, C5, and C6.
The total synthesis approach, recently developed by Myers et al., 12 can modify positions inaccessible (or difficult to access) by semisynthetic methods. Its unique "right-to-left" (ring A to D) mode of construction provides the most efficient means to widely vary substitutions, as well as ring structures, in the D-ring region. 12, 17 StructureÀactivity relationships (SAR) of tetracycline analogs accumulated in the last few decades 14 and the recently solved tetracyclineÀ30S ribosome cocrystal structure 15 indicate that the "southeast" portion of the molecule is directly involved in interactions (mainly H-bonding) with the bacterial ribosome and should be largely conserved in order to retain high levels of ribosomal binding. In contrast, the "northwest" portion of the molecule does not directly interact with the ribosome and can be modified without substantial loss of activity. Structural variations in the D-ring region have emerged as one of the most promising approaches to modify tetracyclines for improved potency and pharmacological properties 13 as shown by previous generations of tetracyclines such as tigecycline, which is highly potent and capable of overcoming tetracycline resistance. 7 Myers et al. 12, 17 recently reported a series of pentacyclic analogs with promising antibacterial activity against both Grampositive and Gram-negative organisms. These analogs were based on a "pentacycline" scaffold (9, Figure 2) , 12, 17 which has an additional benzene ring (E-ring) fused in a linear fashion to the C8 and C9 carbons on the tetracycline D-ring. The added E-ring not only produces a unique tetracycline scaffold but also presents several additional derivatization sites believed to have minimum effect on ribosomal binding as expected from the binding mode of tetracycline with the 30S ribosome. We believe this unique pentacyclic scaffold, coupled with optimal substitutions and substitution patterns, has the potential to uncover new tetracycline analogs that are potent, are capable of overcoming tetracycline resistance, and have improved pharmacological properties such as oral bioavailability. We therefore decided to expand the pentacycline series to include a much wider range of substitutions and substitution patterns. We evaluated the antibacterial activity of the new pentacycline analogs against a wide range of organisms including Gram-positive, Gram-negative, and tetracycline-resistant strains. We also studied in vivo efficacy and pharmacokinetic
' CHEMISTRY
We applied Myers' general synthetic approach 12, 17 for the pentacyclines (9) as outlined in Figure 2 , involving the coupling of various DÀE ring precursors (7) and enone 8 16 via MichaelÀ Dieckmann annulations. Several subseries of pentacyclines with systematic modifications at C7ÀC10 were designed and synthesized according to Schemes 1À10.
Several 10-substituted pentacycline analogs with no substitution at C7 (7-H pentacyclines) or with a dimethylamino group at C7 (7-dimethylamino pentacyclines) were reported recently by Myers et al. 12, 17 and showed promising antibacterial activity against both Gram-positive and Gram-negative organisms. In order to study the effect of different substitutions and substitution patterns on the antibacterial activity of the pentacyclines, we expanded the 7,10-disubstituted pentacycline class to include additional C7 substituents (Cl, F, and CH 3 O) , as well as a wide range of C10 substituents (Scheme 1).
Thus, 6-bromophthalide (10) was treated with lithium diisopropylamide (LDA) and methyl crotonate, followed by treatment with boron trifluoride diethyl etherate according to the Broom and Sammes procedures 18 to yield 7-bromonaphthol 11 (22% yield over two steps). Naphthol 11 was methylated with dimethylsulfate to give naphthalene 12, which was converted to phenyl ester 13 by saponification with aqueous sodium hydroxide, acid chloride formation with oxalyl chloride, and reaction with phenol (86% yield over three steps). The methyl ether of compound 13 was cleaved with BBr 3 , and the resulting phenol was protected using di-tert-butyl dicarbonate ((Boc) 2 O), 4-dimethylaminopyridine (DMAP), and diisopropylethylamine (DIEA), affording the DÀE ring precursor 14a (89% yield over two steps). MichaelÀDieckmann annulation 12 was carried out by deprotonation of 14a with LDA in the presence of enone 8 and N,N,N 0 ,N 0 -tetramethylethylenediamine (TMEDA) in tetrahydrofuran (THF) at À78°C, yielding the desired hexacyclic intermediate 15a (47% yield). Deprotonation with phenyllithium and lithiumÀhalogen exchange with n-butyllithium at À78°C, followed by reaction with N,N-dimethylformamide (DMF) converted 15a to aldehyde 16a in 84% yield. Reductive amination of aldehyde 16a with a series of amines using sodium triacetoxyborohydride gave secondary and tertiary amines 17a. The secondary amine intermediates were also further derivatized by acylation and sulfonylation. Finally, desylilation with aqueous hydrofluoric acid (HF) gave intermediates 18a, which were subjected to palladiumcatalyzed hydrogenation to yield the desired 7-H-10-aminomethyl pentacycline analogs 19a after reverse-phase HPLC purification in about 45À55% overall yields.
A series of 7-chloro, 7-fluoro, and 7-dimethylamino-10-aminomethyl pentacycline analogs were also prepared starting from naphthalene 13 according to Scheme 1. Thus, to prepare the 7-chloro DÀE ring precursor (14b) required for the 7-chloro pentacyclines (19b), compound 13 was regioselectively chlorinated with N-chlorosuccinimide (NCS) to yield phenyl 7-bromo-4-chloro-1-methoxy-3-methylnaphthalene-2-carboxylate, which was demethylated and protected with (Boc) 2 O to give DÀE ring precursor 14b (80% yield over three steps). The 7-fluoro DÀE ring precursor (14c) was prepared as follows. Intermediate 13 was regioselectively iodinated with N-iodosuccinimide (NIS) and trifluoroacetic acid (TFA) in refluxing acetonitrile to give phenyl 7-bromo-4-iodo-1-methoxy-3-methylnaphthalene-2-carboxylate. Selective metalÀiodine exchange with n-butyllithium at À100°C followed by quenching with N-fluorobenzenesulfonimide (NFSI) 19 yielded phenyl 7-bromo-4-fluoro-1-methoxy-3-methylnaphthalene-2-carboxylate (51% yield over two steps), which was converted to DÀE ring precursor 14c by the two-step sequence of demethylation and Boc protection (78% yield over two steps). For the preparation of the 7-dimethylamino DÀE ring precursor (14d), intermediate 13 was nitrated with a mixture of concentrated nitric acid and sulfuric acid in methylene chloride to yield 
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ARTICLE phenyl 7-bromo-1-methoxy-3-methyl-4-nitronaphthalene-2-carboxylate. The methyl ether was cleaved with BBr 3 , and the nitro group was reduced with zinc dust to give phenyl 4-amino-7-bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate. Reductive dimethylation with formaldehyde followed by Boc protection provided DÀE ring precursor 14d in high overall yield. The 7-methoxy DÀE ring precursor (14e) was prepared as follows. Oxidation of phenyl 4-dimethylamino-7-bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate with PhI(OAc) 2 in methanol/1,4-dioxane followed by treatment with zinc dust in acetic acid afforded phenyl 4-methoxy-7-bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate, 20 which was protected with (Boc) 2 O to give the desired DÀE ring precursor 14e (80% yield over two steps). Final analogs (7-chloro, 7-fluoro, and 7-dimethylamino-10-aminomethyl pentacyclines, 19bÀ19e) were then prepared from these DÀE ring precursors (14bÀ14e) using similar procedures as described for the synthesis of 19a in moderate to good yields.
To study the effect of different alkylamino groups at C7, a set of 7-alkylamino-10-azetidinomethyl pentacyclines were synthesized according to was reduced to aniline 21 with zinc dust in 86% yield. Diallylation with excess phenyllithium and allylbromide led to diallylamine 22 (82% yield), which was demethylated with BBr 3 and protected with (Boc) 2 O to yield DÀE ring precursor 23c (46% yield over two steps). Additionally, DÀE ring precursor 23b was derived from intermediate 21 by monoallylation with phenyllithium and allylbromide, demethylation with BBr 3 , and protection of the hydroxyl and secondary amino groups with (Boc) 2 O (39% yield over three steps). Furthermore, intermediate 20 was demethylated with BBr 3 and reduced with Zn dust as described above for the synthesis of analogs 19d. The resulting hydroxyaniline was then protected as the tri-Boc intermediate by treatment with excess (Boc) 2 O in DMF, followed by monodeprotection with dilute TFA in methylene chloride to yield the di-Boc-protected intermediate (34% yield). Methylation of the resulting carbamate by deprotonation with lithium bis(trimethylsilyl)amide (LHMDS) followed by treatment with iodomethane yielded DÀE ring precursor 23a (67% yield over two steps). These three DÀE ring precursors (23aÀ23c) were then annulated with enone 8 to give the bromo intermediates (24aÀ24c) in good yields. Formylation afforded aldehydes 25aÀ25c, which were reductively aminated with azetidine and deprotected to yield the final products 26aÀ26c in moderate yields.
Scheme 3 outlines the preparation of a series of 7-alkoxy-10-azetidinomethyl pentacycline analogs. 4-dimethylamino-7-bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate (27) with PhI(OAc) 2 in the presence of allyl alcohol followed by treatment with zinc dust in acetic acid afforded the corresponding 4-allyloxy naphthol, which was protected with (Boc) 2 conditions (PPh 3 , diisopropyl azodicarboxylate (DIAD)) to yield the 7-alkoxy intermediates 34. Desilylation with aqueous HF, enol ether cleavage with HCl, and hydrogenation gave the desired 7-alkoxy-10-azetidinomethyl pentacycline analogs 35 (25% yield over four steps). Intermediate 30 was also deprotected to give analog 31.
Intermediate 30 was also treated with OsO 4 and N-methylmorpholine-N-oxide (NMO) to give the 1,2-diol 36 (Scheme 4). Oxidative cleavage of 36 with NaIO 4 yielded aldehyde 37. Reductive amination followed by deprotection gave the desired 7-aminoexthoxy-10-azetidinomethyl pentacycline analogs 40 in moderate overall yields. Intermediate 36 was also deprotected to yield analog 38 (28% yield over three steps).
The effect of substitutions at C8 was probed with a set of 8-amino, 8-methoxy, and 8-aminomethyl pentacycline analogs prepared according to Schemes 5, 6, and 7. Thus, 4-bromophthalide 41 (Scheme 5) was converted to 5-bromonaphthol 42 under similar conditions to those used for the preparation of 7-bromonaphthol 11 in 27% overall yield. Naphthol 42 was benzylated with benzyl bromide and potassium carbonate to give compound 43 (77% yield), which was transformed to the corresponding phenyl ester 44 by hydrolysis and ester formation under standard conditions (73% over two steps). Buchwald amination 22 of 44 with BocNH 2 (74% yield), debenzylation by hydrogenation, and reprotection with (Boc) 2 O afforded the tri-Boc-protected intermediate 45 (49% yield over two steps). Benzylic bromination under radical conditions using NBS and dibenzoyl peroxide (BPO) gave the desired DÀE ring precursor 46 in 81% yield. LithiumÀhalogen exchange of benzyl bromide 46 in the presence of enone 8 at À100°C in THF gave the desired cyclized product 47 in 53% yield. Aqueous HF treatment of 47 followed by hydrogenation in the presence or absence of aldehydes yielded the desired 8-amino pentacycline analogs 49 (29% yield over two steps). 5-Bromonaphthalide (62) was converted to 6-bromonaphthol 63 in 20% yield over two steps. Benzylation, hydrolysis, and phenyl ester formation yielded intermediate 64 (46% yield over three steps). Buchwald amination with BocNH 2 gave compound 65 (64% yield), which was debenzylated by hydrogenation and reprotected with (Boc) 2 O to yield compound 66 (90% over two steps). Radical bromination of 66 using NBS and BPO afforded the desired DÀE ring precursor 67 (74% yield). LithiumÀ halogen exchange of benzyl bromide 67 with n-butyllithium in the presence of enone 8 at À100°C in THF gave the cyclized compound 68 (20% yield). Aqueous HF treatment, followed by hydrogenation in the presence or absence of aldehydes yielded the desired 9-amino pentacycline analogs 69 (34À36% yield).
The effect of C10 substitutions was explored with a set of 10-fluoro pentacycline analogs prepared according to Scheme 9. Bromonaphthalene 14d was treated with n-butyllithium followed by NFSI to afford DÀE ring precursor 70 (60% yield), which was cyclized with enone 8 to give compound 71d in low yield (9%). Bromo intermediates 15a, 15b, and 15e were also converted to the corresponding fluoro intermediates 71a, 71b, and 71c in moderate yields under similar conditions. Desilylation and hydrogenation of 71aÀ71d yielded the desired 10-fluoro pentacycline analogs 72aÀ72d in 60À70% yields over two steps.
Scheme 10 outlines the synthesis of a series of 10-aryl pentacyclines. Suzuki coupling of bromo intermediate 15a with aryl boronic acids afforded intermediates 73 in good yields. Journal of Medicinal Chemistry ARTICLE These were deprotected as described above to yield the desired 10-aryl pentacycline analogs 75 in moderate yields.
' RESULTS AND DISCUSSION
The synthesized pentacycline analogs were evaluated for antibacterial activity using a panel of tetracycline-sensitive and tetracycline-resistant Gram-positive and Gram-negative bacteria strains, and their minimum inhibitory concentrations (MICs) are shown in Tables 1À4.  Table 1 shows the MIC data for analogs with the C10 substituent fixed as an azetidinomethyl group in combination with various C7 substituents (7-substituted-10-azetidinomethyl Journal of Medicinal Chemistry ARTICLE pentacyclines). While the 7-Cl analog (19b-1) was slightly less potent than the parent compound (19a-9) and the 7-F analog (19c-5) was equipotent to 19a-9, the 7-CH 3 O and 7-(CH 3 ) 2 N analogs (19e-6 and 26d) were more potent than the parent against most Gram-positive strains, with the 7-CH 3 O analog (19e-6) being the most potent compound in the series. Higher alkoxy groups at C7 (31 and 35a) did not improve potency, while alkoxy groups containing additional polar or basic groups (35b, 38, 40a, and 33a) greatly reduced potency against most strains in the panel. Among the 7-amino pentacyclines (26aÀ26d), the 7-(CH 3 ) 2 N analog (26d) was the most potent overall. It is clear that tertiary amines (26c and 26d) at C7 are preferred over secondary amines (26a and 26b). Potency against Gramnegative strains decreases with increasing alkyl group size among the 7-alkoxy and 7-alkylamino analogs. The 7-alkoxy analogs appear to have better activity against Gram-negative organisms. It is important to note that several analogs, especially the 7-CH 3 O analog (19e-6) , displayed good potency against all Gram-positive resistant strains (tetK and tetM) in the panel (MIC = 0.0625À2 μg/mL) and their tetM activity is usually better than that of minocycline. However, these analogs are not as potent as tigecycline against most strains in the panel. Table 2 outlines the antibacterial activity of analogs in which the C10 substitution was varied while keeping C7 constant as H. Among the 10-aryl analogs, compounds 75a and 75b (10-phenyl and 10-(3-pyridinyl) ) had similar activity to the unsubstituted parent compound (19a-1) against most strains except S. pneumoniae, while the p-dimethylaminophenyl analog (75c) had almost no Journal of Medicinal Chemistry ARTICLE activity across the board. On the other hand, the various 10-aminomethyl analogs, especially the 10-(CH 3 ) 2 NCH 2 analog (19a-6), displayed good antibacterial activity, particularly against the Gram-positive strains. , as well as nonbasic aminomethyl groups at C10 (19a-19) , lead to decreased potency. It is clear that small basic alkylamines (C1ÀC6) are preferred at the C10 benzylic position for improved activity against both Gram-positive and Gram-negative organisms. Introduction of additional polar or basic groups decreased activity in general (19a-12 to 19a-16) . It is interesting that while the had similar activity to the parent compound (19a-1) against Gram-positive strains and better activity against Gram-negative strains, the 3,3-di-F-azetidinomethyl analog (19a-18) had almost no activity against Gram-negative strains. It is likely that the azetidine nitrogen is only weakly basic due to the gem,gem-difluoro substitutions. Table 3 shows the antibacterial activity of analogs with various combinations of C7 and C10 substituents. All 10-aminomethyl pentacycline analogs bearing a F, Cl, CH 3 O, or (CH 3 ) 2 N group at C7 had good potency in general, especially against Grampositive bacteria. While the 7-CH 3 O-10-azetidinomethyl analog (19e-6) was the most active analog and the had the least activity among this 10-aminomethyl pentacycline series, the variation at C7 from F to Cl, CH 3 O, and (CH 3 ) 2 N did not drastically alter the analogs' potency. As for the C10 substituents, the analogs were able to maintain good potency as Journal of Medicinal Chemistry ARTICLE long as a small alkylaminomethyl group (C1ÀC6) is present, as also indicated by data in Table 2 . Heterosubstitutions on this C10 moiety decrease overall activity as shown by analog 19d-2. While the 10-fluoro analogs (72aÀ72d) maintained potency against most Gram-positive strains, they are much less active than the corresponding 10-aminomethyl analogs against the two S. pneumoniae strains and all the Gram-negative strains. Although the 7-CH 3 O-10-azetidinylmethyl analog (19e-6) had comparable activity to tigecycline against most Gram-positive strains (except EF159), most other analogs were less potent in general, especially against Gram-negative organisms.
The antibacterial activity of the O, and 9-amino pentacycline analogs is shown in Table 4 .
Most had similar or decreased activity relative to the parent compound (19a-1). Analogs with an 8-aminomethyl group (61aÀ61c) had decreased activity against the tetM strains (SA161, EF159, and SP160) but maintained activity against the tetK strain (SA158). While analogs with an amino group at C8 or C9 (49aÀ49c, 69a, 69b) had decreased potency overall, the 8-methoxy analog (54) maintained activity against the S. aureus and E. faecalis strains but had significantly decreased activity against the S. pneumoniae strains. As data in previous tables has shown, a proper combination of substitutions at the C7 and C10 positions, particularly a methoxy group at C7 and a small aminomethyl group at C10, is preferred for increased overall potency. Since analogs in Table 4 do not have any Journal of Medicinal Chemistry ARTICLE substitution at C10, it is possible that additional substitution at C10 would result in analogs with increased activity. Pharmacokinetic (PK) measurements in SpragueÀDawley rats and in vivo efficacy studies in a mouse septicemia model were performed on a selected set of pentacycline analogs (Table 5 ). The 7-H analogs appear to have lower clearances and higher AUC's than the 7-CH 3 O and 7-F analogs. While compounds 19a-17 and 19c-5 are closely related analogs, differing only in the position of the fluorine atom, their V z and other PK parameters are quite different. Due to the extremely poor exposure of 19c-5, its exceptionally large V z probably has little meaning. In terms of oral bioavailability, three out of the four analogs with oral bioavailability (%F) of greater than 10% are compounds with fluorine either at C7 or on the C10 side chain (19a-17, 19c-6, and 19e-7) , with both 19a-17 and 19e-7 having oral bioavailability of about 18%. Compound 19a-17 also showed similar oral bioavailability in cynomolgus monkeys. A number of analogs displayed very good in vivo efficacy in the mouse septicemia model with PD 50 values ranging from less than 0.3 to 0.62 mg/kg when dosed intravenously, while both tetracycline and tigecycline had a similar PD 50 of 0.35 mg/kg in the same model. Compound 19a-17 was also dosed orally in the septicemia model and showed a PD 50 of 12.2 mg/kg. As a comparison, tetracycline had an oral bioavailability of 12% and an oral PD 50 of 8.1 mg/kg in these models, while tigecycline had almost no oral bioavailability in the rats.
' CONCLUSIONS
Employing a highly efficient total synthesis approach, we have prepared diverse and novel pentacycline analogs with systematic variations at C7, C8, C9, and C10. The in vitro and in vivo antibacterial activities of these pentacycline analogs were evaluated, and their structureÀactivity relationships (SAR) were analyzed. All pentacycline analogs retain a varying degree of activity against most strains used in the screening panel, especially Gram-positive organisms. This provides additional evidence that the "northwest" portion of the molecule is not directly involved in binding with the ribosome. It is observed that certain combinations of substitutions at both C7 and C10 can enhance the pentacyclines' overall potency. For example, analogs with a methoxy group at C7 and a small basic alkylaminomethyl group at C10 are the most potent pentacyclines against both susceptible and resistant Gram-positive organisms, while nonbasic substituents at C10 generally do not improve potency. These observations should prove to be valuable for further SAR studies of pentacyclines and other tetracycline classes. Although all pentacycline analogs prepared so far are less potent in vitro than tigecycline, a number of analogs showed in vivo efficacy comparable to tigecycline when dosed intravenously in a mouse septicemia model. Several analogs had promising oral bioavailability in rats and cynomolgus monkeys, while tigecycline had almost no oral bioavailability in rats. Moreover, compound 19a-17, a 10-(3-fluoroazetidino)methyl pentacycline analog, showed promising in vivo efficacy comparable to tetracycline when dosed orally in the mouse septicemia model. We believe pentacycline analogs such as compound 19a-17, or future analogs derived from this unique scaffold, have the potential to be further developed as oral and iv agents against resistant Gram-positive pathogens. This study demonstrates that the total synthesis approach can give access to novel and potent tetracycline analogs, such as the pentacyclines and azatetracyclines, 24 that would be inaccessible through semisynthetic methods.
' EXPERIMENTAL SECTION Chemistry. All commercially available solvents, including anhydrous solvents, and reagents were used without further purification. All reactions under dry conditions were performed under nitrogen atmospheres. Reductive aminations with amine salts were performed in the presence of equal equivalents of triethylamine in addition to other reagents. 1 H and 13 C NMR (nuclear magnetic resonance) spectra were recorded on a 400 MHz JEOL ECX-400 spectrometer. Thin layer chromatography (TLC) analysis was performed on Merck silica-gel 60 F 254 and visualized under UV light. Flash chromatography was performed on Merck silica gel 60 (40À43 μm). Purity of tested compounds was determined to be g95% by reverse-phase analytical HPLC/MS analysis (high performance liquid chromatography/mass spectrometry) performed on a Waters Alliance system (column, SunFire C18, 5 μm, 4.6 Â 50 mm 2 ; solvent A, water with 0.1% formic acid; solvent B, acetonitrile with 0.1% formic acid; MS detector, Waters 3100). Reversephase preparative HPLC was performed on a Waters Autopurification system (for purification of intermediates, column, SunFire Prep C18 OBD, 5 μm, 19 Â 50 mm 2 ; flow rate, 20 mL/min; solvent A, water with 0.1% formic acid; solvent B, acetonitrile with 0.1% formic acid; fraction collection, mass-directed; for purification of final products, column, Polymerx RP-1 100A, 10 μm, 150 Â 21.20 mm 2 ; flow rate, 20 mL/min; solvent A, water with 0.05 N HCl; solvent B, acetonitrile; fraction collection, mass-directed).
Methyl 7-Bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate (11) . A solution of n-butyllithium in hexanes (2.50 M, 48.4 mL, 121.1 mmol, 1.2 equiv) was added to a solution of diisopropylamine (17.0 mL, 121.1 mmol, 1.2 equiv) in THF (400 mL) at À78°C. The solution was vigorously stirred at À78°C for 30 min, warmed to 0°C for 5 min, and cooled back to À78°C. A solution of 6-bromophthalide 25 (10, 21 .5 g, 100.9 mmol, 1.0 equiv) in THF (200 mL) was added slowly via a cannula. The resulting dark solution was allowed to slowly warm to À50°C over 3 h. Methyl crotonate (11.8 mL, 111 .0 mmol, 1.1 equiv) was added slowly, and the resulting mixture was allowed to warm to rt Table 5 . Pharmacokinetic Profiles and in Vivo Efficacy of Pentacyclines a Measured in SpragueÀDawley rats (n = 3). Animals were fasted overnight (minimum of 12 h) and given a single oral (10 mg/kg) or iv (1 mg/kg) dose followed by a sampling scheme for 24À48 h. Sterile water was used as vehicle. PK parameters were calculated by noncompartmental analysis using WinNonlin. ND = not determined.
b SA, Staphylococcus aureus. c Determined in a mouse septicemia model (SA100, ATCC 13709). See Experimental Section for details. Numbers in parentheses are 95% CI values.
without removing the cooling bath. The reaction mixture was poured into 1 N HCl (600 mL) and extracted with ethyl acetate (200 mL Â 3). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated and dried under high vacuum, providing an orange foamy solid (27.5 g), which was used for the next reaction without further treatment.
The above crude product was dissolved in methylene chloride (250 mL). BF 3 ÀEt 2 O (2.52 mL, 20.2 mmol, 0.2 equiv) was added dropwise at rt. The resulting brownish mixture was stirred at rt for 1 h and poured into 0.5 N HCl (600 mL). The organic layer was separated, and the aqueous layer was extracted with methylene chloride (200 mL Â 2). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated, providing a thick brownish oil. Purification by flash column chromatography (5% f 10% ethyl acetateÀhexanes) afforded compound 11 as an off-white solid (6.32 g, 22%, two steps): Methyl 7-Bromo-1-methoxy-3-methylnaphthalene-2-carboxylate (12) . Cesium carbonate powder (9.06 g, 27.8 mmol, 1.3 equiv) and dimethyl sulfate (2.43 mL, 25.7 mmol, 1.2 equiv) were added to a solution of 11 (6.31 g, 21.0 mmol, 1.0 equiv) in acetone (60 mL). The mixture was heated at reflux for 1 h, cooled to rt, and filtered through a short pad of Celite. The Celite cake was washed thoroughly with acetone. The filtrate was concentrated to afford 12 as a white solid, which was used for the next reaction directly without further purification.
Phenyl 7-Bromo-1-methoxy-3-methylnaphthalene-2-carboxylate (13) . A mixture of ethanol (10 mL) and 4 N aqueous sodium hydroxide (10 mL) was added to compound 12. The suspension was stirred at 85°C overnight. The resulting clear solution was cooled to rt, acidified with 4 N HCl (pH 3, 11 mL), and extracted with methylene chloride (30 mL Â 4). The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated to afford the carboxylic acid as a pale solid.
Oxalyl chloride (2.24 mL, 25.7 mmol, 1.2 equiv) was added to a solution of the above carboxylic acid in anhydrous methylene chloride (100 mL) at rt, followed by a couple of drops of DMF (gas evolution). The mixture was stirred at rt for 1 h and the volatiles evaporated under reduced pressure. The residue was dried under high vacuum to give the crude acid chloride. This was redissolved in dry methylene chloride (100 mL). Pyridine (3.46 mL, 42.8 mmol, 2.0 equiv), phenol (2.11 g, 22. 5 mmol, 1.05 equiv), and DMAP (catalytic amount) were added. The reaction mixture was stirred for several hours at rt, diluted with 1 N HCl (100 mL), and extracted with methylene chloride (50 mL Â 3). The combined organic extracts were washed with brine (40 mL) and dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash column chromatography (5% f 10% ethyl acetateÀhexanes) to afford the desired product 13 as a white solid (6.86 
H).
Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-3-methylnaphthalene-2-carboxylate (14a). A solution of BBr 3 in methylene chloride (1.0 M, 5.83 mL, 5.83 mmol, 2.0 equiv) was added slowly over 4 min to a solution of compound 13 (1.08 g, 2.91 mmol, 1.0 equiv) in methylene chloride (60 mL) at À70°C. The resulting orange solution was allowed to warm to À45°C over 5 h and poured into saturated aqueous sodium bicarbonate (100 mL). The mixture was stirred at rt for 10 min and extracted with methylene chloride (60 mL Â 3). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated, providing the naphthol intermediate as a white solid, which was used in the next reaction without further purification. 7, 151.2, 150.5, 144.9, 134.0, 133.4, 131.6, 129.5, 128.9, 126.9, 126.7, 126.3, 124.5, 124.0, 121.7, 120.9, 84.6, 27.5, 20.7 . 6-dioxo-4,4a,6,13,13a,14,-14a,15-octahydropentaceno[2,3-d] isoxazol-7-yl tert-Butyl Carbonate (15a). MichaelÀDieckmann Cyclization, General Procedure A. A solution of LDA (1.8 M, 4.30 mL, 7.74 mmol, 3 .0 equiv) in heptane/ ethylbezene/THF was added dropwise via a syringe to a solution of compound 14a (2.36 g, 5.16 mmol, 2.0 equiv), enone 8 (1.24 g, 2.58 mmol, 1.0 equiv), and TMEDA (2.32 mL, 15.5 mmol, 6.0 equiv) in THF (100 mL) at À78°C. The resulting red-orange solution was allowed to warm to À10°C over 2 h and diluted with aqueous potassium phosphate buffer (pH 7.0, 0.2 M, 50 mL) and saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate (200 mL Â 2). The organic extracts were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the crude product, which was purified by flash column chromatography (5% f 10% ethyl acetateÀhexanes) to afford the MichaelÀ Dieckmann cyclization product 15a as an orange solid (1.02 g, 47%): 6-dioxo-4,4a,6,13,13a,14,-14a,15-octahydropentaceno[2,3-d] isoxazol-7-yl tert-Butyl Carbonate (16a). Formylation, General Procedure B. A solution of phenyllithium in di-n-butyl ether (1.8 M, 0.20 mL, 0.36 mmol, 2.0 equiv) was added dropwise to a solution of compound 15a (153 mg, 0.18 mmol, 1.0 equiv) in THF (9 mL) at À78°C. The resulting red solution was stirred at À78°C for 5 min. n-Butyllithium (94 μL, 2.5 M/hexanes, 0.24 mmol, 1.3 equiv) was added dropwise at À78°C. The reaction was stirred at À78°C for 5 min. Dry DMF (69 μL, 0.90 mmol, 5.0 equiv) was added. The deep red reaction mixture was stirred at À78°C for 1 h. Saturated aqueous ammonium chloride (10 mL) was added dropwise at À78°C. Aqueous potassium phosphate buffer (pH 7.0, 0.2 M, 10 mL) was added. The reaction mixture was allowed to warm to rt and extracted with methylene chloride (30 mL Â 3). The organic extracts were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative reverse-phase HPLC to afford the desired product 16a (121 mg, 84%) as a yellow solid: R f = 0.15 (25% ethyl acetateÀhexanes); 1 2, 181.7, 167.5, 140.5, 138.7, 135.0, 134.7, 129.5, 128.5, 128.48, 128.45, 128.42, 126.8, 126.0, 123.9, 120.7, 108.5, 108.4, 84.9, 81.8, 72.5, 61.2, 46.4, 41.8, 39.9, 28.4, 27.7, 26.0, 22.7, 19.0, À2.6, À3.8 ,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-6) . Reductive Amination, General Procedure C. Dimethylamine (44 μL, 2.0 M/THF, 0.088 mmol, 7.0 equiv), acetic acid (5 μL, 0.088 mmol, 7.0 equiv), and sodium triacetoxyborohydride (19 mg, 0.088 mmol, 7 .0 equiv) were added to a solution of aldehyde 16a (10 mg, 0.012 mmol, 1.0 equiv) in 1,2-dichloroethane (1 mL) at rt. After being stirred for 2 h, the reaction mixture was poured into aqueous potassium phosphate buffer (pH = 7.0, 10 mL). The mixture was extracted with methylene chloride (15 mL Â 3). The combined organic extracts were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the crude product.
Desilylation, General Procedure D. Concentrated aqueous hydrofluoric acid (48 wt %, 0.3 mL) was added to a solution of the above crude product in acetonitrile (0.6 mL) in a polypropylene reaction vessel at rt. The mixture was vigorously stirred at rt overnight and poured into aqueous dipotassium hydrogen phosphate (3.6 g in 25 mL water). The mixture was extracted with ethyl acetate (20 mL Â 3). The combined organic extracts were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the crude product as a yellow solid.
Hydrogenation, General Procedure E. Methanol (3 mL) was added to the above crude product. 10% PdÀC (catalytic amount) was added in one portion at rt. An atmosphere of hydrogen was introduced by briefly evacuating the flask and flushing with hydrogen (1 atm). The reaction mixture was stirred at rt for 4 h and filtered through a pad of Celite. The filtrate was concentrated to give the crude product, which was purified by preparative reverse-phase HPLC to yield the desired product (19a-6) as a yellow solid (3.6 mg, HCl salt, 51%, three steps): The following compounds were prepared similarly to 19a-6 using aldehyde 16a and the respective amines according to general procedures C, D, and E.
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[(methylamino)methyl]-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-2). (4S,4aS,5aR,14aS)-4-(Dimethylamino) -3,12,14,14a-tetrahydroxy-1,13-dioxo-10-[(propylamino)methyl]-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-3) . ,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-4) . (4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-10-{[(2-methoxyethyl)amino]methyl}-1, 13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-5 -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-7 -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-8 3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-9 
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-10-(pyrrolidin-1-ylmethyl) -1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-10 
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-10-(piperidin-1-ylmethyl) -1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-11 (4S,4aS,5aR,14aS)-4-(Dimethylamino) -3,12,14,14a-tetrahydroxy-10-[(3-hydroxyazetidin-1-yl) ,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-12) . (4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-10-[(3-methoxyazetidin-1-yl)methyl]-1, 13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-13) . (4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-{[3-(dimethylamino)-azetidin-1-yl]methyl} -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,-5a,6,13,14a-octahydropentacene-2-carboxamide (19a-14) . (4S,4aS,5aR,14aS)-10-{[3-(Acetylamino)azetidin-1-yl]methyl}-4-(dimethylamino) -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,-13,14a-octahydropentacene-2-carboxamide (19a-15 -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-16 ,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-17) . Prepared from aldehyde 16a (1.08 g, 1.36 mmol, 1.0 equiv) and 3-fluoroazetidine according to General Procedures C, D, and E. The final product was purified by preparative reverse-phase HPLC using water (with 0.5% trifluoroacetic acid (TFA)) and acetonitrile as the mobile phases (474 mg, 45%, three steps, TFA salt).
To a solution of the above TFA salt of compound 19a-17 (269 mg, 0.345 mmol, 1 equiv) in methanol (5 mL) was added methanesulfonic acid (44.8 μL, 0.691 mmol, 2 equiv). The solvent was removed under reduced pressure; the residue was dissolved in water (3.75 mL) and acetonitrile (1.25 mL) and then freeze-dried to provide the desired product as the dimesylate salt (256 mg, 100%): (4S,4aS,5aR,14aS)-10-[(3,3-Difluoroazetidin-1-yl)methyl]-4-(dimethylamino) -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19a-18) . (4S,4aS,5aR,14aS)-4-(Dimethylamino) -3,12,14,14a-tetrahydroxy--10-{[methyl(methylsulfonyl) amino]methyl}-1, 13-dioxo-1,4,4a,5,5a,6, 13,14a-octahydropentacene-2-carboxamide (19a-19) . Methylamine (68 μL, 8.0 M/ethanol, 0.54 mmol, 7.0 equiv), acetic acid (31 μL, 0.54 mmol, 7.0 equiv), and sodium triacetoxyborohydride (115 mg, 0.54 mmol, 7.0 equiv) were added to a solution of aldehyde 16a (62 mg, 0.078 mmol, 1.0 equiv) in 1,2-dichloroethane (4 mL) at rt. After being stirred for 5 h, the reaction mixture was quenched by saturated aqueous sodium bicarbonate (10 mL) and aqueous potassium phosphate buffer (pH 7.0, 0.2 M, 10 mL). The mixture was extracted with methylene chloride (15 mL Â 3). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated to give the methylamino intermediate.
2,6-Lutidine (4.3 μL, 0.037 mmol, 3.0 equiv) and methanesulfonyl chloride (2.9 μL, 0.037 mmol, 3.0 equiv) were added to a solution of the above methylamino intermediate (10 mg, 0.012 mmol, 1.0 equiv) in anhydrous methylene chloride (0.6 mL). The reaction was stirred at rt for 6 h and concentrated. The residue was purified by preparative reverse-phase HPLC to afford the desired methylsulfonamide intermediate, which was subjected to desilylation and hydrogenation according to General Phenyl 7-Bromo-4-chloro-1-methoxy-3-methylnaphthalene-2-carboxylate. A suspension of NCS (396 mg, 2.96 mmol, 1.1 equiv) and compound 13 (1.00 g, 2.69 mmol, 1.0 equiv) in acetonitrile (27 mL) was heated at reflux for overnight. The reaction mixture was cooled to rt, and solvents were evaporated. The crude product (white solid) was dried under high vacuum and used directly for the next step.
Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-4-chloro-3-methylnaphthalene-2-carboxylate (14b). A solution of BBr 3 in methylene chloride (1.0 M, 5.38 mL, 5.38 mmol, 2.0 equiv) was added slowly to a solution of the above crude compound (2.69 mmol, 1.0 equiv) in methylene chloride (30 mL) at À65°C. The resulting red solution was stirred at À65°C for 55 min and was poured into saturated aqueous sodium bicarbonate (100 mL). The mixture was stirred at rt for 30 min and extracted with methylene chloride (60 mL Â 4). The organic extracts were combined and dried over anhydrous magnesium sulfate. 8, 150.3, 142.7, 132.3, 131.2, 130.7, 129.9, 129.5, 127.3, 126.5, 126.3, 125.4, 124.5, 121.9, 121.5, 84.8, 27.4, 18.3 ; MS (ESI) m/z 489.18, 491.10 (M À H).
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-9-bromo-4a-{[tert-butyl-(dimethyl)silyl]oxy}-12-chloro-15-(dimethylamino)-5-hydroxy-4, 6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[ 2,3-d] Phenyl 7-Bromo-4-fluoro-1-methoxy-3-methylnaphthalene-2-carboxylate. NIS (2.57 g, 11.4 mmol, 1.3 equiv) and TFA (0.20 mL, 2.63 mmol, 0.3 equiv) were added to a suspension of compound 13 (3.26 g, 8. 78 mmol, 1.0 equiv) in acetonitrile (90 mL) at rt. The mixture was then stirred at 80°C for 25 h. The reaction mixture was cooled to rt, and solvents were evaporated. The resulting off-white solid was dissolved in methylene chloride (250 mL) and the methylene chloride solution was washed with saturated aqueous sodium bicarbonate (200 mL). The aqueous layer was extracted with methylene chloride (50 mL Â 2). The combined organic phase was dried over magnesium sulfate, filtered, and concentrated to afford the iodo intermediate as a To a solution of the above iodo intermediate in THF (135 mL) at À100°C (liquid nitrogen/ethanol bath) was added n-butyllithium (4.25 mL, 1.6 M/hexanes, 6.80 mmol, 1.0 equiv) dropwise. After the mixture was stirred at that temperature for 5 min, a solution of NFSI (Nfluorobenzenesulfonimide, 2.57 g, 8.16 mmol, 1.2 equiv) in THF (17 mL) was added dropwise via a cannula. The resulting reaction mixture was warmed slowly to À78°C and kept at that temperature for 1 h. Phosphate buffer (pH 7.0, 200 mL) was added to quench the reaction. The resulting mixture was warmed to rt and extracted with ethyl acetate (200 mL). The organic layer was separated, washed with saturated aqueous sodium bicarbonate (150 mL) and brine (100 mL), dried over magnesium sulfate, filtered, and concentrated to afford a yellow solid, which was purified by flash column chromatography (0 f 1% ethyl acetateÀhexanes) to afford phenyl 7-bromo-4-fluoro-1-methoxy-3-methylnaphthalene-2-carboxylate (pale yellow solid, 1.30 g, 51%, two steps): 1 Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-4-fluoro-3-methylnaphthalene-2-carboxylate (14c). A solution of BBr 3 in methylene chloride (1.0 M, 3.67 mL, 3.67 mmol, 1.1 equiv) was added slowly to a solution of phenyl 7-bromo-4-fluoro-1-methoxy-3-methylnaphthalene-2-carboxylate (1.30 g, 3.34 mmol, 1.0 equiv) in methylene chloride (40 mL) at À78°C. The resulting red solution was stirred at À78°C for 45 min and was poured into saturated aqueous sodium bicarbonate (250 mL). The mixture was stirred at rt for 30 min and extracted with methylene chloride (300 mL Â 1, 120 mL Â 3). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated, providing the crude product as an off-white solid.
(Boc) 2 O (765 mg, 3.51 mmol, 1.05 equiv) and DMAP (10 mg, 0.08 mmol, 0.02 equiv) were added to a solution of the above crude product in methylene chloride (40 mL). The reaction mixture was stirred for 50 min at rt and concentrated. The residue was purified by flash column chromatography (1% f 3% ethyl acetateÀhexanes) to afford compound 14c (off-white solid, 1. 6-dioxo-4,4a,6,-13,13a,14,14a,15-octahydropentaceno[ 2,3-d] (4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-7-fluoro-3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19c-5). Compound 16c was subjected to reductive amination with azetidine (39 μL, 0.57 mmol, 3.0 equiv), desilylation, and hydrogenation according to General Procedures C, D, and E to yield the desired product 19c-5 as a yellow solid (57 mg, 47%, three steps) The following compounds were prepared similarly from compound 16c and the respective amines.
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-10-[(ethylamino)methyl]-7-fluoro-3,12,14,14a-tetrahydroxy-1, 13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19c-1 (4S,4aS,5aR,14aS)-4-(Dimethylamino)-7-fluoro-3,12,14,14a-tetrahydroxy-1,13-dioxo-10-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19c-7). Phenyl 7-Bromo-1-methoxy-3-methyl-4-nitronaphthalene-2-carboxylate (20). A mixture of freshly mixed nitric acid (68À70%) and concentrated sulfuric acid (4:5 v/v, 0.6 mL) was added dropwise to a solution of compound 13 (2.74 g, 7.38 mmol, 1.0 equiv) in methylene chloride (25 mL) at 0°C. The resulting yellow solution was stirred at 0°C for 25 min. Additional nitric acid (68À70%) and concentrated sulfuric acid (4:5 v/v, 0.66 mL) were added dropwise. The reaction mixture was stirred at 0°C for 1.5 h and neutralized with 6 N aqueous sodium hydroxide (5.5 mL). Saturated aqueous sodium bicarbonate (100 mL) was added. The organic layer was separated, and the aqueous layer was extracted with methylene chloride (80 mL Â 2). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated, providing the title compound 20 as a light yellow solid: 1 
Phenyl 4-Amino-7-bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate. A solution of BBr 3 in methylene chloride (1.0 M, 14.8 mL, 14.8 mmol, 2.0 equiv) was added slowly over 7 min to a solution of phenyl 7-bromo-1-methoxy-3-methyl-4-nitronaphthalene-2-carboxylate (20) in methylene chloride (74 mL) at À70°C. The resulting red solution was allowed to warm to À45°C in 2 h and was poured into saturated aqueous sodium bicarbonate (200 mL). The mixture was stirred at rt for 30 min and extracted with methylene chloride (300 mL Â 2). The aqueous layer was further extracted with ethyl acetate (150 mL Â 2). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered through a short plug of silica gel, and the filtrate was concentrated, providing the crude product as a yellow solid (2.62 g).
Zinc dust (1.93 g, 29.52 mmol, 4.0 equiv) was added slowly to a solution of the above intermediate in a mixture of THF (30 mL) and acetic acid (6 mL) in one portion at 0°C. The mixture was stirred vigorously for 60 h at rt. The reaction mixture was filtered through a pad of Celite. The Celite cake was washed thoroughly with ethyl acetate. The filtrate was washed with saturated aqueous sodium bicarbonate (350 mL) and brine (100 mL). The organic phase was dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated, providing the title compound as a yellow solid (2.73 g, quantitative) .
Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-4-(dimethylamino)-3-methyl-2-naphthoate (14d). Formic acid (37 wt % in water, 0.78 mL, 10.5 mmol, 5.4 equiv), acetic acid (0.60 mL, 10.5 mmol, 5.4 equiv), and sodium triacetoxyborohydride (2.23 g, 10.5 mmol, 5.4 equiv) were added to a solution of phenyl 4-amino-7-bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate (730 mg, 1.96 mmol, 1.0 equiv) in acetonitrile (35 mL) and THF (20 mL). The reaction mixture was stirred at rt for 3.5 h and quenched by slowly adding saturated aqueous sodium bicarbonate (80 mL). The resulting clear mixture was extracted with ethyl acetate (50 mL Â 3). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated to give the crude intermediate phenyl 7-bromo-1-hydroxy-4-(dimethylamino)-3-methyl-2-naphthoate (27) .
(Boc) 2 O (470 mg, 2.16 mmol, 1.1 equiv), DIEA (0.61 mL, 3.50 mmol, 1.8 equiv), and DMAP (20 mg, 0.16 mmol, 0.08 equiv) were added to a solution of the above intermediate 27 in methylene chloride (35 mL). The reaction mixture was stirred for 1 h at rt, diluted with methylene chloride (100 mL), and washed with a mixture of brine and saturated aqueous sodium bicarbonate (1:1, 100 mL). The organic phase was separated and dried over magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash column chromatography (1% f 5% ethyl acetateÀhexanes) to afford compound 14d as a yellow foamy solid (976 mg -9-formyl-5-hydroxy-4,6-dioxo-4,4a,-6,13,13a,14,14a,15-octahydropentaceno[2,3-d] 7, 187.2, 182.5, 181.7, 167.5, 151.3, 145.3, 143.6, 138.4, 134.9, 134.4, 129.8, 128.5, 128.4, 127.3, 125.8, 125.4, 121.3, 108.3, 84.7, 81.7, 72.5, 61.0, 46.4, 43.2, 41.8, 35.7, 28.2, 27.6, 26.0, 22.7, 18.9, À2.6, À3.8; HRMSÀESI (m/z) ,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19d-1) . Compound 16d was subjected to reductive amination with methylamine (33 wt % in ethanol, 14 μL, 0.11 mmol, 7.0 equiv), desilylation, and hydrogenation according to General Procedures C, D, and E to yield compound 19d-1 as a yellow solid (4.4 mg, 41% for three steps) The following compounds were prepared similarly from compound 16d and the respective amines.
(4S,4aS,5aR,14aS)-4,7-Bis(dimethylamino) -3,12,14,14a-tetrahydroxy-10-{[(2-methoxyethyl) amino]methyl}-1, 13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19d-2 3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19d-3 (4S,4aS,5aR,14aS)-4,7-Bis(dimethylamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-10-(pyrrolidin-1-ylmethyl) -1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19d-4 Phenyl 7-Bromo-1-hydroxy-4-methoxy-3-methylnaphthalene-2-carboxylate. PhI(OAc) 2 (2.20 g, 6 .84 mmol, 2.0 equiv) was added in one portion to a solution of phenyl 7-bromo-1-hydroxy-4-(dimethylamino)-3-methyl-2-naphthoate (27, 1.37 g, 3. 42 mmol, 1.0 equiv) in a mixture of methanol (20 mL) and 1,4-dioxane (20 mL) at 0°C. The reaction mixture was stirred at 0°C for 8 min. Acetic acid (4 mL) and zinc dust (1.34 g, 20.5 mmol, 6 .0 equiv) were added at 0°C. The reaction mixture was stirred at 0°C for 10 min and filtered through a pad of Celite. The Celite cake was washed thoroughly with ethyl acetate. The filtrate was washed with 6 N aqueous sodium hydroxide (11 mL), saturated aqueous sodium bicarbonate (120 mL), and brine (50 mL). The organic phase was dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated, providing the title compound as a yellow solid: 4, 152.4, 151.3, 150.5, 140.5, 131.5, 129.5, 128.1, 127.8, 126.3, 125.3, 124.8, 124.7, 124.2, 121.6, 121.4, 84.6, 61.7, 27.5, 13.4. (4aS,13aR,14aS -hydroxy-12-methoxy-4,6-dioxo-4,4a,-6,13,13a,14,14a,15-octahydropentaceno[2,3-d] isoxazol-7-yl tert-Butyl Carbonate (15e). Compound 14e (1.56 g, 3.20 mmol, 1.5 equiv) was reacted with enone 8 (1.03 g, 2.13 mmol, 1.0 equiv) according to General Procedure A to yield compound 15e as a yellow solid (829 mg, 45%): (4aS,13aR,14aS,15S)-3-(Benzyloxy)-4a-{[tert-butyl(dimethyl)silyl]-oxy}-15-(dimethylamino) -9-formyl-5-hydroxy-12-methoxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d] isoxazol-7-yl tertButyl Carbonate (16e). Compound 15e (589 mg, 0.67 mmol, 1.0 equiv) was converted to compound 16e according to General Procedure B (366 mg, 66%, yellow solid): (4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino) -3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19e-6) . Compound 16e (273 mg, 0.33 mmol, 1.0 equiv) was subjected to reductive amination with azetidine (45 μL, 0.66 mmol, 2.0 equiv) to afford compound 17e-6 (MS (ESI) m/z 866.76 (M þ H)), followed by desilylation and hydrogenation according to General Procedures C, D, and E to yield compound 19e-6 as a yellow solid (156 mg, 74%, three steps):
1 H NMR (400 MHz, CD 3 The following compounds were prepared similarly from compound 16e and the respective amines.
(4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-10-[(propylamino)methyl]- 1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19e-1) . (4S,4aS,5aR,14aS)-10-[(Cyclopropylamino)methyl]-4-(dimethylamino) -3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a, 6,13,14a-octahydropentacene-2-carboxamide (19e-2) . 3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19e-4) . ,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19e-5) . 3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-1,4,4a,5,5a,-6,13,14a-octahydropentacene-2-carboxamide (19e-7) . (4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-7-methoxy-1,13-dioxo-10-(pyrrolidin-1-ylmethyl) -1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (19e-8) . Phenyl 4-Amino-7-bromo-1-methoxy-3-methylnaphthalene-2-carboxylate (21). Acetic acid (2 mL) and zinc dust (622 mg, 9.52 mmol, 4 equiv) were added to a solution of compound 20 (990 mg, 2.38 mmol, 1.0 equiv) in THF (10 mL) at rt. The reaction mixture was stirred at rt for 15 h. More zinc dust (311 mg, 4.76 mmol, 2 equiv) was added. The reaction mixture was stirred for another 5 h and filtered through a Celite pad. The Celite cake was washed with ethyl acetate. The filtrate was washed with saturated aqueous sodium bicarbonate and brine. The organic phase was dried over sodium sulfate and filtered. The filtrate was concentrated. The residue was purified by flash column chromatography (20% ethyl acetateÀhexanes containing 10% methylene chloride) to afford the aniline product 21 (791 mg, 86%) as a yellow solid.
Phenyl 4-[Allyl(tert-butoxycarbonyl)amino]-7-bromo-1-[(tert-butoxycarbonyl)oxy]-3-methyl-2-naphthoate (23b). A solution of phenyllithium in di-n-butyl ether (1.8 M, 0.61 mL, 1.10 mmol, 1.2 equiv) was added dropwise to a solution of aniline 21 (354 mg, 0.92 mmol, 1.0 equiv) in THF (18 mL) at À78°C. After 5 min, allylbromide (0.11 mL, 1.28 mmol, 1.4 equiv) was added dropwise at À78°C. The reaction mixture was allowed to warm up to rt over 1 h 40 min, and saturated aqueous ammonium chloride was added. The resulting mixture was stirred for 5 min and extracted with ethyl acetate (40 mL Â 3). The combined organic extracts were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated, and the residue was purified by flash column chromatography (0% f 5% ethyl acetate/hexanes) to afford the monoallyl intermediate (325 mg, 83%) as a colorless solid: 6, 150.6, 148.5, 139.7, 136.0, 130.4, 129.7, 129.3, 128.2, 126.3, 126.2, 125.6, 125.1, 123.4, 121.5, 120.3, 116.4, 63.8, 53.0, 15.1. A solution of BBr 3 in methylene chloride (1.0 M, 0.61 L, 0.61 mmol, 2.0 equiv) was added dropwise to a solution of the above monoallyl intermediate (130 mg, 0.30 mmol, 1.0 equiv) in methylene chloride (3 mL) at À30°C. The resulting yellow solution was stirred between À30 to À25°C for 1.5 h and was poured into saturated aqueous sodium bicarbonate. The mixture was warmed to rt and extracted with methylene chloride (25 mL Â 3). The organic extracts were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude product (Boc) 2 O (96 mg, 0.44 mmol, 2.0 equiv) and DMAP (3 mg, 0.02 mmol, 0.1 equiv) were added to a solution of the above intermediate in DMF (1 mL) . The reaction was stirred at rt overnight, diluted with ethyl acetate (50 mL), and washed with water (30 mL Â 4). The organic phase was dried over anhydrous sodium sulfate. The dried solution was filtered and concentrated. The residue was purified by flash column chromatography (5% f 7% ethyl acetateÀhexanes) to afford compound 23b (colorless oil, 88 mg, 47%, two steps, 3:1 rotamers): 1.25 (s, 6.75 H) .
Phenyl 7-Bromo-4-(diallylamino)-1-methoxy-3-methyl-2-naphthoate (22) . A solution of phenyllithium in di-n-butyl ether (1.8 M, 0.35 mL, 0.64 mmol, 1.2 equiv) was added dropwise to a solution of aniline 21 (206 mg, 0.53 mmol, 1.0 equiv) in THF (10 mL) at À78°C. After 3 min, allylbromide (0.16 mL, 1.86 mmol, 1.5 equiv) was added dropwise at À78°C. The reaction mixture was allowed to warm up to rt over 30 min. The reaction was recooled to À78°C. Additional phenyllithium in di-nbutyl ether (0.35 mL, 1.8 M/di-n-butyl ether, 0.636 mmol, 1.2 equiv) and allylbromide (0.16 mL, 1.86 mmol, 1.5 equiv) were added. The reaction was allowed to warm to rt over 40 min and quenched with saturated aqueous ammonium chloride. The mixture was stirred for 5 min and extracted with ethyl acetate (40 mL Â 3). The organic extracts were combined and dried over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The residue was purified by flash column chromatography (0% f 2% ethyl acetate/hexanes) to afford the diallyl compound 22 (205 mg, 82%) as a pale yellow oil: Phenyl 7-Bromo-1-[(tert-butoxycarbonyl)oxy]-4-(diallylamino)-3-methyl-2-naphthoate (23c). A solution of BBr 3 in methylene chloride (1.0 M, 2.22 mL, 2.22 mmol, 2.0 equiv) was added dropwise to a solution of compound 22 (517 mg, 1.11 mmol, 1.0 equiv) in methylene chloride (11 mL) at À40°C. The resulting light orange suspension was stirred between À40 and À30°C for 1 h and was poured into saturated aqueous sodium bicarbonate. The mixture was warmed to rt and stirred for 30 min. The mixture was extracted with methylene chloride (60 mL Â 3). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered and concentrated. The crude product was used directly for the next reaction. 7.47À7.43 (m, 2 H), 7.31À7.27 (m, 3 H), 5.90À5.80 (m, 2 H), 5.15À5.04 (m, 4 H), 2.54 (s, 3 H), 1.48 (s, 9 H) . (methyl)amino]-1-[(tertbutoxycarbonyl)oxy]-3-methyl-2-naphthoate (23a). Phenyl 4-amino-7-bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate (2.0 g, 5.37 mmol, 1.0 eq, crude) was dissolved in DMF (30 mL). (Boc) 2 O (2.34 g, 10.75 mmol, 2.0 equiv) and DMAP (30 mg, 0.24 mmol, 0.04 equiv) were added. The brownish reaction mixture was stirred at rt for 3.5 h. The reaction mixture was diluted with ethyl acetate (300 mL) and washed with brine (150 mL Â 3). The organic phase was dried over magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated. TLC analysis indicated incomplete reaction. The residue was then redissolved in DMF (30 mL). (Boc) 2 O (2.34 g, 10.75 mmol, 2.0 equiv) and DMAP (20 mg, 0.16 mmol, 0.03 equiv) were added. The mixture was stirred at rt for 42 h. The reaction mixture was diluted with ethyl acetate (300 mL) and washed with water (200 mL Â 2) and brine (200 mL). The organic phase was dried over magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash column chromatography (15% f 25% ethyl acetateÀhexanes) to afford the tri-Boc-protected product (white solid, 1.24 g, 34%) 
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ARTICLE TFA (0.71 mL, 9.22 mmol, 5.0 equiv) was added to a solution of the above tri-Boc-protected compound (1.24 g, 1.84 mmol, 1.0 equiv) in methylene chloride (60 mL) at 0°C. The solution was stored in a refrigerator (4°C) overnight. Saturated aqueous sodium bicarbonate was added slowly at 0°C, and the mixture was warmed to rt. The mixture was extracted with methylene chloride (50 mL Â 3). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated, providing the O-Boc and N-mono-Boc intermediate as a white foamy solid.
The above crude compound was dissolved in THF (30 mL). A solution of LHMDS in THF (1.0 M, 2.76 mL, 2.76 mmol, 1.5 equiv) was added dropwise to the reaction at À78°C. The resulting orange mixture was stirred at À78°C for 20 min. Iodomethane (0.23 mL, 3.68 mmol, 2.0 equiv) was added slowly. The reaction mixture was slowly warmed to rt and stirred overnight. Saturated ammonium chloride was added. The reaction mixture was extracted with ethyl acetate (100 mL Â 1, 50 mL Â 2). The organic extracts were combined and dried over anhydrous magnesium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash column chromatography (10% f 20% ethyl acetateÀhexanes) to give compound 23a (6 1.21 (s, 7.8 H) . 6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno-[2,3-d] 1.61 (s, 9 H), 1.27 (s, 9 H), 0.82 (s, 9 H), 0.28 (s, 3 H), 0.15 (s, 3 H) 4a, 6, 13, 13a, 14, 14a, . Compound 24a (93 mg, 0.096 mmol, 1.0 equiv) was converted to compound 25a according to General Procedure B. The crude product was purified by preparative reverse-phase HPLC (45 mg, 51%, a mixture of rotamers, yellow solid):
1 H NMR (400 MHz, CDCl 3 ) δ 15.84, 15.97 (s, 1 H), 10.21, 10.19 (s, 1 H), 8.69, 8.65 (s, 1 H), 8.16À8.14 (m, 1 H), 7.90À7.84 (m, 1 H), 7.53À7.50 (m, 2 H), 7.42À7.35 (m, 3 H), 5.38 (s, 2 H), 4.02, 3.99 (d, J = 10.4 Hz, 1 H), 3.28, 3.19 (s, 3 H), 3.28À2.99 (m, 2 H), 2.68À2.49 (m, 9 H) , 2.18À2.14 (m, 1 H), 1.62, 1.61 (s, 9 H), 1.27, 1.24 (s, 9 H), 0.85, 0.82 (s, 9 H), 0.26, 0.25 (s, 3 H), 0.16 (s, 3 H) ; MS (ESI) m/z 924.68 (M þ H).
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino) -3,12,14,14a-tetrahydroxy-7-(methylamino)-1,13-dioxo-1,4,4a,5,5a,6,-13,14a-octahydropentacene-2-carboxamide (26a) . Compound 25a was subjected to reductive amination with azetidine, followed by desilylation and hydrogenation according to general procedures C, D, and E to yield compound 26a (23% over three steps) 4aS, 13aR, 14aS, -hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d] 1.27, 1.26 (s, 9 H), 0.84, 0.81 (s, 9 H), 0.29, 0.28 (s, 3 H), 0.15, 0.14 (s, 3 H) .
(4aS,13aR,14aS,15S)-3-(Benzyloxy)-9-bromo-4a-{[tert-butyl(dimethyl) silyl]oxy}-12-(diallylamino) -15-(dimethylamino)-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d] 1.26 (s, 9 H), 0.85 (s, 9 H), 0.29 (s, 3 H), 0.15 (s, 3 H) . 9-formyl-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d] 1.27, 1.26 (s, 9 H), 0.84, 0.82 (s, 9 H), 0.29, 0.28 (s, 3 H), 0.16, 0.14 (s, 3 H) . -9-formyl-5-hydroxy-4,6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[ 2,3-d] isoxazol-7-yl tert-Butyl Carbonate (25c). Prepared from compound 24c according to General Procedure B:
1 H NMR (400 MHz, CDCl 3 ) δ 15.85 (br s, 1 H), 10.18 (s, 1 H), 8.61 (br s, 1 H), 8.23 (d, J = 8.5 Hz, 1 H), 8.07 (dd, J = 1.2, 8.5 Hz, 1 H), 7.52À7.50 (m, 2 H), 7.41À7.34 (m, 3 H), 5.99À5.89 (m, 1 H), 5.83À5.73 (m, 1 H), 5.39, 5.35 (ABq, J = 12.2 Hz, 2 H), 5.20À5.01 (m, 4 H), 4.00 (d, J = 10.4 Hz, 1 H), 3.94À3.71 (m, 4 H), 3.52 (dd, J = 4.3, 15.9 Hz, 1 H), 3.02À2.97 (m, 1 H), 2.67À2.46 (m, 9 H), 2.20 (d, J = 14.0 Hz, 1 H), 1.61 (s, 9 H), 0.86 (s, 9 H), 0.30 (s, 3 H), 0.16 (s, 3 H) .
(4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino) -3,12,14,14a-tetrahydroxy-1,13-dioxo-7-(propylamino)-1,4,4a,5,5a,6,-13,14a-octahydropentacene-2-carboxamide (26b) . (4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-7-(dipropylamino) -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,-6,13,14a-octahydropentacene-2-carboxamide (26c (15 mL Â 3) . The organic extracts were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product (MS (ESI) m/z 968.81 (M þ H)).
The above crude product was subjected to desilylation according to General Procedure D, and the crude desliylated product was purified by preparative reverse-phase HPLC. This intermediate was dissolved in methanol (0.5 mL). Concentrated HCl (0.5 mL) was added slowly at rt. The reaction mixture was stirred at rt for 36 h and poured into aqueous dipotassium hydrogenphosphate (3 g dissolved in 30 mL water). The mixture was extracted with methylene chloride (15 mL Â 5). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was subjected to hydrogenation according to General Procedure E to yield compound 35b (4.3 mg, 25% over four steps): 1 3,12,14,14a-tetrahydroxy-7-isopropoxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (35a) . Prepared similarly to compound 35b from compound 32 and isopropanol: 4a, 6, 13, 13a, 14, 14a, . N-Methylmorpholine-N-oxide (60 mg, 0.52 mmol, 4.0 equiv) was added to a solution of compound 30 (115 mg, 0.129 mmol, 1.0 equiv) in THF (3 mL) and water (0.6 mL). A solution of OsO 4 in water (4 wt %, 30 μL, 0.04 equiv) was added. The reaction mixture was stirred at rt overnight, diluted with aqueous Na 2 S 2 O 3 (2 M, 10 mL) and brine (10 mL), and extracted with methylene chloride (20 mL Â 2). The organic extracts were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 36: -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,-13,14a-octahydropentacene-2-carboxamide (38) . Prepared from compound 36 by desilylation and hydrogenation according to General Procedures D and E (28% over three steps): (4S,4aS,5aR,14aS)-10-(Azetidin-1-ylmethyl)-4-(dimethylamino)-3,12,14,14a-tetrahydroxy-1,13-dioxo-7-(2-oxoethoxy) -1,4,4a,5,5a,6,-13,14a-octahydropentacene-2-carboxamide (37) . NaIO 4 (72 mg, 0.34 mmol, 3.0 equiv) was added to a solution of compound 36 (0.11 mmol, 1.0 equiv) in THF (1.5 mL) and water (1.5 mL) at 0°C. The reaction mixture was stirred between 0 and 8°C for 24 h, diluted with aqueous Na 2 S 2 O 3 solution (2 M, 15 mL) and brine (15 mL) , and extracted with methylene chloride (20 mL Â 3). The organic extracts were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 37. ,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (40a Methyl 5-Bromo-1-hydroxy-3-methylnaphthalene-2-carboxylate (42). A solution of n-butyllithium in hexane (2.5 M, 12.0 mL, 30.0 mmol, 1.2 equiv) was added slowly to a stirred solution of diisopropylamine (4.25 mL, 30.0 mmol, 1.2 equiv) in anhydrous THF (100 mL) at À78°C. The solution was stirred at À78°C for 30 min. 4-Bromophthalide 26 (5.38 g, 25 mmol, 1 equiv) in anhydrous THF (20 mL) was added dropwise. The mixture was then warmed to À50°C over 3 h. Methyl crotonate (2.95 mL, 27.5 mmol, 1.1 equiv) was slowly added. The reaction mixture was gradually warmed to rt, stirred overnight, and poured into dilute HCl (1 N, 150 mL). The mixture was extracted with ethyl acetate (50 mL Â 3). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude intermediate.
The above crude intermediate was redissolved in methylene chloride (65 mL). BF 3 ÀEt 2 O (0.63 mL, 5.00 mmol, 0.2 equiv) was added dropwise. The reaction was stirred at rt for 1 h and quenched with water (100 mL). The organic layer was separated, and the aqueous layer was further extracted with methylene chloride (50 mL Â 3). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography (100:1 f 50:1, petroleum etherÀethyl acetate) to give the desired product 42 Phenyl 1-(Benzyloxy)-5-bromo-3-methylnaphthalene-2-carboxylate (44). To a solution of compound 43 (2.0 g, 5.2 mmol) in absolute ethanol (10 mL) was added aqueous sodium hydroxide (4 N, 10 mL). The mixture was heated at reflux overnight. The reaction was cooled to rt, diluted with water (30 mL), and extracted with ethyl acetate (20 mL Â 3, discarded). The aqueous phase was acidified with dilute HCl (1 N, 45 mL) to pH ≈ 6, and the mixture was extracted with ethyl acetate (40 mL Â 3). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the carboxylic acid intermediate as a white solid.
To a solution of the above crude product in methylene chloride (20 mL) was added oxalyl chloride (0.57 mL, 6.5 mmol, 1.3 equiv) and a few drops of DMF (gas evolution). The solution was stirred at rt for 30 min, and the volatiles were evaporated under reduced pressure. The residue was further dried under high vacuum to afford the crude benzoyl chloride. This crude benzoyl chloride was redissolved in dry methylene chloride (20 mL). Pyridine (0.88 mL, 10.9 mmol, 2.1 equiv), phenol (0.54 g, 5.7 mmol, 1.1 equiv), and DMAP (catalytic amount) were added. The solution was stirred at rt for 1 h. The solvent was evaporated. To a stirred solution of the above aminated intermediate (2.0 g, 4.13 mmol, 1.0 equiv) in methanol (20 mL) was added 10% PdÀC (300 mg). The suspension was briefly evacuated and refilled with hydrogen, and the mixture was stirred under a hydrogen atmosphere (1 atm) at rt for 1 h. The reaction mixture was filtered through a small Celite pad and the filtrate was concentrated under reduced pressure. The residue was redissolved in methylene chloride (20 mL). Boc 2 O (1.25 g, 5.73 mmol, 1.4 equiv) and a catalytic amount of DMAP (30 mg, 0.25 mmol, 0.06 equiv) were added. The solution was stirred at rt for 2 h. The reaction was quenched with brine (50 mL) and extracted with methylene chloride (30 mL Â 3). The combined organic extracts were dried, filtered, and concentrated. 6-dioxo-4,4a,6,13,13a,14,14a,15-octahydropentaceno[2,3-d] isoxazol-11-yl]imidodicarbonate (47). A solution of n-butyllithium in hexane (2.5 M, 0.30 mL, 0.75 mmol, 3.2 equiv) was added dropwise to a solution of 46 (504 mg, 0.75 mmol, 3.2 equiv) and enone 8 (113 mg, 0.23 mmol, 1.0 equiv) in dry THF (10 mL) at À100°C (liquid N 2 /ethanol bath). The reaction was stirred at À100°C for 30 min, allowed to warm to 0°C gradually, quenched with brine (20 mL), and extracted with ethyl acetate (20 mL Â 3). The combined organic extracts were dried, filtered, and concentrated. The residue was purified by flash chromatography (30:1 f 20:1 f 10:1, petroleum etherÀethyl acetate) to give the desired product 47 (123 mg, 53%) as a yellow semisolid: (4S,4aS,5aR,14aS)-8-Amino-4-(dimethylamino) -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (49a) . (4S,4aS,5aR,14aS)-4-(Dimethylamino)-3,12,14,14a-tetrahydroxy-8-(methylamino) -1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (49b) . The Boc and TBS protection groups of compound 47 (70 mg, 0.071 mmol) were removed according to General Procedure D. One half of this crude product (20 mg, 0.035 mmol, 1.0 equiv) was dissolved in 1 N HCl/methanol (4 mL). Formalin (0.06 mL, 0.74 mmol, 21 equiv) and 10% PdÀC (7.0 mg) were added. The suspension was briefly evacuated and refilled with hydrogen. The mixture was stirred at rt under a hydrogen atmosphere (1 atm) for 3 h. The catalyst was filtered off, and the filtrate was concentrated under reduced pressure to yield the crude product. The crude product was purified by preparative HPLC to give the desired product 49b (4.5 mg, 23%) as a yellow solid: (4S,4aS,5aR,14aS)-4,8-Bis(dimethylamino) -3,12,14,14a-tetrahydroxy-1,13-dioxo-1,4,4a,5,5a,6,13,14a-octahydropentacene-2-carboxamide (49c) . Prepared from the same precursor (30 mg, 0.053 mmol, 1.0 equiv) under similar hydrogenation conditions used for compound 49b, except that the reaction was performed at 40À50°C overnight (4.0 mg, 15%, yellow solid): Phenyl 1-(Benzyloxy)-5-methoxy-3-methyl-2-naphthoate (50). A mixture of compound 44 (2.2 g, 4.93 mmol, 1.0 equiv), bis-(pinacolato)diboron (7.5 g, 29.5 mmol, 6 .0 equiv), potassium acetate (3.0 g, 30.6 mmol, 6.2 equiv) , and PdCl 2 (dppf)ÀCH 2 Cl 2 (400 mg, 0.5 mmol, 0.1 equiv) in 1,4-dioxane (50 mL) was degassed and stirred at 90°C under a nitrogen atmosphere overnight. The reaction mixture was cooled to rt and filtered. The filtrate was concentrated. The residue was purified by column chromatography (100:1, petroleum etherÀethyl acetate) to afford the borate intermediate To a solution of the above borate intermediate (2.0 g, 4.0 mmol, 1.0 equiv) in THF (20 mL) was carefully added H 2 O 2 (30%, 2.0 mL, 17.6 mmol, 4.4 equiv), followed by acetic acid (1.2 mL, 20.0 mmol, 5.0 equiv). The reaction was stirred at rt overnight, quenched with saturated aqueous NaHSO 3 solution (until starch iodide test was negative), and extracted with ethyl acetate (50 mL Â 3). The combined organic extracts were dried, filtered, and concentrated. equiv) was slowly added. The reaction was gradually warmed to rt with stirring overnight. The reaction mixture was poured into dilute HCl (1 N, 150 mL) and extracted with ethyl acetate (50 mL Â 3). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated to dryness.
The above crude intermediate was redissolved in methylene chloride (400 mL). BF 3 ÀEt 2 O (5.1 mL, 40 mmol, 0.2 equiv) was added dropwise. The reaction was stirred at rt for 1 h and quenched with water (200 mL). The organic layer was separated, and the aqueous layer was extracted with methylene chloride (100 mL Â 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography (50:1 f 30:1, petroleum etherÀethyl acetate) to give the desired product 63 (12 g, 20%) Phenyl 1-(Benzyloxy)-6-bromo-3-methylnaphthalene-2-carboxylate (64). To a stirred solution of compound 63 (10.7 g, 36.3 mmol, 1.0 equiv) in acetone (250 mL) was added powdered potassium carbonate (10.0 g, 72.5 mmol, 2.0 equiv) and benzylbromide (7.4 g, 43 .5 mmol, 1.2 equiv). The mixture was refluxed for 2 h, cooled to rt, and concentrated. The residue was purified by flash chromatography (1:0 f 10:1, petroleum etherÀethyl acetate) to give the benzyl ether intermediate (9.1 g, 65%) as a white solid: To a solution of the above benzyl ether intermediate (12.5 g, 32 .4 mmol) in absolute ethanol (50 mL) was added dilute aqueous sodium hydroxide (4 N, 50 mL). The mixture was heated at reflux overnight, cooled to rt, diluted with water (150 mL), and extracted with ethyl acetate (50 mL Â 3, discarded). The aqueous phase was acidified with dilute HCl (1 N, 220 mL) to pH ≈ 6 and extracted with ethyl acetate (50 mL Â 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the carboxylic acid as a white solid.
To a solution of above crude product in methylene chloride (250 mL) was added oxalyl chloride (6.13 mL, 65.0 mmol, 2.0 equiv) and a few drops of DMF (gas evolution). The mixture was stirred at rt for 30 min, and the volatiles were evaporated under reduced pressure. The residue was further dried under high vacuum to afford the crude benzoyl chloride. This crude benzoyl chloride was redissolved in dry methylene chloride (200 mL). Pyridine (5.14 g, 65.0 mmol, 2.0 equiv), phenol (3.66 g, 39.0 mmol, 1.2 equiv) , and a catalytic amount of DMAP were added. The mixture was stirred at rt for 1 h. The solvent was evaporated. The residue was suspended in ethyl acetate and filtered. The filtrate was washed with 1 N HCl (three times), H 2 O, saturated aqueous sodium bicarbonate, and brine. The solution was dried over sodium sulfate, filtered, and concentrated. The residue was purified by flash chromatography (1:0 f 10:1, petroleum etherÀethyl acetate) to give compound 64 (1.7 g, 71%) as an off-white solid:
